세계의 CMO/CDMO 생명공학 시장 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2033년)

Persistence Market Research has recently published an in-depth analysis of the global CMO/CDMO (Contract Manufacturing Organization/Contract Development and Manufacturing Organization) biotechnology market. The report provides a comprehensive evaluation of key market dynamics, including growth drivers, trends, opportunities, and challenges, delivering a thorough understanding of the market landscape.

Key Insights:

• CMO/CDMO Biotechnology Market Size (2024E): USD 23.1 Bn
• Projected Market Value (2033F): USD 33.6 Bn
• Global Market Growth Rate (CAGR 2024 to 2033): 5.5%

CMO/CDMO Biotechnology Market - Report Scope:

The CMO/CDMO biotechnology market represents a crucial segment in the biopharmaceutical industry, focusing on the outsourcing of manufacturing and development services for biotech products. This market includes a wide range of services, such as drug development, manufacturing, and commercialization, provided by specialized organizations to biopharma companies. The sector is characterized by its role in accelerating drug development timelines, reducing operational costs, and enhancing manufacturing capabilities. The market's expansion is driven by the growing demand for biotech therapies, increasing complexity in drug development, and the need for flexible and scalable manufacturing solutions.

Market Growth Drivers:

The CMO/CDMO biotechnology market is fueled by several key factors, including the rising demand for biologics and personalized medicine. Biopharma companies are increasingly outsourcing manufacturing to CMO/CDMO providers to leverage their specialized expertise, advanced technologies, and cost efficiencies. The shift towards biologics and complex drugs, coupled with the need for rapid market entry and flexibility, drives the growth of the CMO/CDMO sector. Additionally, the increasing prevalence of chronic diseases and the growing focus on novel drug therapies contribute to the rising demand for outsourced biotech manufacturing services.

Market Restraints:

Despite its growth potential, the CMO/CDMO biotechnology market faces challenges such as regulatory complexities, intellectual property concerns, and high competition. Navigating the regulatory landscape for biotech products requires adherence to stringent standards, which can be challenging for CMO/CDMO providers. Intellectual property issues related to drug formulations and processes may also pose risks. Furthermore, the market is highly competitive, with numerous players vying for contracts, which can impact pricing and profit margins.

Market Opportunities:

The CMO/CDMO biotechnology market offers substantial growth opportunities driven by technological advancements, increasing investments in biopharma, and expanding therapeutic areas. Innovations in biomanufacturing technologies, such as single-use systems and continuous manufacturing, present opportunities for market players to enhance efficiency and reduce costs. The rise of biologics and gene therapies opens new avenues for CMO/CDMO providers to cater to niche segments and develop specialized services. Strategic collaborations between CMO/CDMO firms and biopharma companies can also drive market growth and foster innovation.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the CMO/CDMO biotechnology market globally?
• Which CMO/CDMO services and therapeutic areas are experiencing significant demand?
• How are technological advancements reshaping the competitive landscape of the CMO/CDMO market?
• Who are the key players in the CMO/CDMO biotechnology market, and what strategies are they employing to maintain a competitive edge?
• What are the emerging trends and future prospects in the global CMO/CDMO biotechnology market?

Competitive Intelligence and Business Strategy:

Leading players in the global CMO/CDMO biotechnology market, such as Lonza Group, Catalent, and Samsung Biologics, emphasize innovation, service differentiation, and strategic partnerships to enhance their market position. These companies invest in advanced manufacturing technologies, expand their service portfolios, and forge alliances with biopharma firms to strengthen their competitive edge. Focus on operational excellence, regulatory compliance, and customer-centric solutions is critical for maintaining market relevance and driving growth in the highly competitive CMO/CDMO sector.

Key Companies Profiled:

• Patheon N.V.
• Catalent
• Samsung Biologics Co., Ltd
• Lonza.
• Boehringer Ingelheim
• Samsung BioLogics
• AGC Biologics, Inc.
• WuXi Biologics
• AbbVie Inc
• Avid Bioservices, Inc.
• Fujifilm Diosynth Biotechnologies
• Xpress Biologic
• Rentschler Biopharma SE
• KBI Biopharma (JSR Corporation)
• Cytovance Biologics

Key Segments Covered in CMO/CDMO Biotechnology Industry Research

By Service:

• Stand-Alone Services
• Integrated

By Product:

• Monoclonal Antibodies
• Antibody Fragments
• Recombinant Therapeutic Proteins
• Viral Vector
• Cell and Gene Therapy
• Vaccine

By Expression System:

• Mammalian
• Microbial
• Bacteria
• Yeast

By Company Size:

• Small
• Mid-Sized
• Large
• Very Large

By Scale of Operations:

• Pre-clinical
• Clinical
• Commercial

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Service Adoption Analysis
• 4.2. Key Regulations
• 4.3. Key promotional Strategies, By Key Players
• 4.4. PESTEL Analysis
• 4.5. Service Pricing Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global CMO/CDMO Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Spending
  • 5.2.2. Growing Lifestyle Disease Prevalence
  • 5.2.3. Cost of Services
  • 5.2.4. Service Adoption Rate
  • 5.2.5. Advancements in Technology
  • 5.2.6. Changes in Regulatory Policies
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Services
  • 6.1.2. By Product
  • 6.1.3. By Expression Systems
  • 6.1.4. By Company Size
  • 6.1.5. By Scale of Operations
  • 6.1.6. By Country
• 6.2. 2024 Market Scenario

7. Global CMO/CDMO Biotechnology Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Services

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Services, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Services, 2024-2033
  • 8.3.1. Stand-Alone Services
    • 8.3.1.1. Cell Line Development
    • 8.3.1.2. Development and Bio Manufacturing
    • 8.3.1.3. Analytical Services
    • 8.3.1.4. Fill finish
    • 8.3.1.5. Packaging
    • 8.3.1.6. Clinical Supply Services
  • 8.3.2. Integrated
• 8.4. Market Attractiveness Analysis By Services

9. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Product

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product, 2024-2033
  • 9.3.1. Monoclonal Antibodies
  • 9.3.2. Antibody Fragments
  • 9.3.3. Recombinant Therapeutic Proteins
  • 9.3.4. Viral Vector
  • 9.3.5. Cell and Gene Therapy
  • 9.3.6. Vaccine
• 9.4. Market Attractiveness Analysis By Product

10. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Expression Systems

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis, By Expression Systems, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Expression Systems, 2024-2033
  • 10.3.1. Mammalian
  • 10.3.2. Microbial
    • 10.3.2.1. Bacteria
    • 10.3.2.2. Yeast
• 10.4. Market Attractiveness Analysis By Expression Systems

11. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Company Size

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis, By Company Size, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Company Size, 2024-2033
  • 11.3.1. Small
  • 11.3.2. Mid-sized
  • 11.3.3. Large
  • 11.3.4. Very large
• 11.4. Market Attractiveness Analysis By Company Size

12. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Scale of Operation

• 12.1. Introduction / Key Findings
• 12.2. Historical Market Size (US$ Bn) Analysis, By Scale of Operation, 2019-2023
• 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Scale of Operation, 2024-2033
  • 12.3.1. Preclinical
  • 12.3.2. Clinical
  • 12.3.3. Commercial
• 12.4. Market Attractiveness Analysis By Scale of Operation

13. Global CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
  • 13.3.1. North America
  • 13.3.2. Latin America
  • 13.3.3. Europe
  • 13.3.4. East Asia
  • 13.3.5. South Asia
  • 13.3.6. Oceania
  • 13.3.7. Middle East and Africa (MEA)
• 13.4. Market Attractiveness Analysis By Region

14. North America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. U.S.
    • 14.3.1.2. Canada
  • 14.3.2. By Services
  • 14.3.3. By Product
  • 14.3.4. By Expression Systems
  • 14.3.5. By Company Size
  • 14.3.6. By Scale of Operation
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Services
  • 14.4.3. By Product
  • 14.4.4. By Expression Systems
  • 14.4.5. By Company Size
  • 14.4.6. By Scale of Operation
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Players - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. U.S. CMO/CDMO Biotechnology Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Services
      • 14.8.1.2.2. By Product
      • 14.8.1.2.3. By Expression Systems
      • 14.8.1.2.4. By Company Size
      • 14.8.1.2.5. By Scale of Operation
  • 14.8.2. Canada CMO/CDMO Biotechnology Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Services
      • 14.8.2.2.2. By Product
      • 14.8.2.2.3. By Expression Systems
      • 14.8.2.2.4. By Company Size
      • 14.8.2.2.5. By Scale of Operation

15. Latin America CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Mexico
    • 15.3.1.2. Brazil
    • 15.3.1.3. Argentina
    • 15.3.1.4. Rest of Latin America
  • 15.3.2. By Services
  • 15.3.3. By Product
  • 15.3.4. By Expression Systems
  • 15.3.5. By Company Size
  • 15.3.6. By Scale of Operation
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Services
  • 15.4.3. By Product
  • 15.4.4. By Expression Systems
  • 15.4.5. By Company Size
  • 15.4.6. By Scale of Operation
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Players - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Mexico CMO/CDMO Biotechnology Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Services
      • 15.8.1.2.2. By Product
      • 15.8.1.2.3. By Expression Systems
      • 15.8.1.2.4. By Company Size
      • 15.8.1.2.5. By Scale of Operation
  • 15.8.2. Brazil CMO/CDMO Biotechnology Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Services
      • 15.8.2.2.2. By Product
      • 15.8.2.2.3. By Expression Systems
      • 15.8.2.2.4. By Company Size
      • 15.8.2.2.5. By Scale of Operation
  • 15.8.3. Argentina CMO/CDMO Biotechnology Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Services
      • 15.8.3.2.2. By Product
      • 15.8.3.2.3. By Expression Systems
      • 15.8.3.2.4. By Company Size
      • 15.8.3.2.5. By Scale of Operation

16. Europe CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. Germany
    • 16.3.1.2. Italy
    • 16.3.1.3. France
    • 16.3.1.4. U.K.
    • 16.3.1.5. Spain
    • 16.3.1.6. BENELUX
    • 16.3.1.7. Russia
    • 16.3.1.8. Rest of Europe
  • 16.3.2. By Services
  • 16.3.3. By Product
  • 16.3.4. By Expression Systems
  • 16.3.5. By Company Size
  • 16.3.6. By Scale of Operation
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Services
  • 16.4.3. By Product
  • 16.4.4. By Expression Systems
  • 16.4.5. By Company Size
  • 16.4.6. By Scale of Operation
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Players - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. Germany CMO/CDMO Biotechnology Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Services
      • 16.8.1.2.2. By Product
      • 16.8.1.2.3. By Expression Systems
      • 16.8.1.2.4. By Company Size
      • 16.8.1.2.5. By Scale of Operation
  • 16.8.2. Italy CMO/CDMO Biotechnology Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Services
      • 16.8.2.2.2. By Product
      • 16.8.2.2.3. By Expression Systems
      • 16.8.2.2.4. By Company Size
      • 16.8.2.2.5. By Scale of Operation
  • 16.8.3. France CMO/CDMO Biotechnology Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Services
      • 16.8.3.2.2. By Product
      • 16.8.3.2.3. By Expression Systems
      • 16.8.3.2.4. By Company Size
      • 16.8.3.2.5. By Scale of Operation
  • 16.8.4. U.K. CMO/CDMO Biotechnology Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Services
      • 16.8.4.2.2. By Product
      • 16.8.4.2.3. By Expression Systems
      • 16.8.4.2.4. By Company Size
      • 16.8.4.2.5. By Scale of Operation
  • 16.8.5. Spain CMO/CDMO Biotechnology Market Analysis
    • 16.8.5.1. Introduction
    • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.5.2.1. By Services
      • 16.8.5.2.2. By Product
      • 16.8.5.2.3. By Expression Systems
      • 16.8.5.2.4. By Company Size
      • 16.8.5.2.5. By Scale of Operation
  • 16.8.6. BENELUX CMO/CDMO Biotechnology Market Analysis
    • 16.8.6.1. Introduction
    • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.6.2.1. By Services
      • 16.8.6.2.2. By Product
      • 16.8.6.2.3. By Expression Systems
      • 16.8.6.2.4. By Company Size
      • 16.8.6.2.5. By Scale of Operation
  • 16.8.7. Russia CMO/CDMO Biotechnology Market Analysis
    • 16.8.7.1. Introduction
    • 16.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.7.2.1. By Services
      • 16.8.7.2.2. By Product
      • 16.8.7.2.3. By Expression Systems
      • 16.8.7.2.4. By Company Size
      • 16.8.7.2.5. By Scale of Operation

17. East Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Services
  • 17.3.3. By Product
  • 17.3.4. By Expression Systems
  • 17.3.5. By Company Size
  • 17.3.6. By Scale of Operation
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Services
  • 17.4.3. By Product
  • 17.4.4. By Expression Systems
  • 17.4.5. By Company Size
  • 17.4.6. By Scale of Operation
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Players - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China CMO/CDMO Biotechnology Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Services
      • 17.8.1.2.2. By Product
      • 17.8.1.2.3. By Expression Systems
      • 17.8.1.2.4. By Company Size
      • 17.8.1.2.5. By Scale of Operation
  • 17.8.2. Japan CMO/CDMO Biotechnology Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Services
      • 17.8.2.2.2. By Product
      • 17.8.2.2.3. By Expression Systems
      • 17.8.2.2.4. By Company Size
      • 17.8.2.2.5. By Scale of Operation
  • 17.8.3. South Korea CMO/CDMO Biotechnology Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Services
      • 17.8.3.2.2. By Product
      • 17.8.3.2.3. By Expression Systems
      • 17.8.3.2.4. By Company Size
      • 17.8.3.2.5. By Scale of Operation

18. South Asia CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. India
    • 18.3.1.2. Indonesia
    • 18.3.1.3. Malaysia
    • 18.3.1.4. Thailand
    • 18.3.1.5. Rest of South Asia
  • 18.3.2. By Services
  • 18.3.3. By Product
  • 18.3.4. By Expression Systems
  • 18.3.5. By Company Size
  • 18.3.6. By Scale of Operation
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Services
  • 18.4.3. By Product
  • 18.4.4. By Expression Systems
  • 18.4.5. By Company Size
  • 18.4.6. By Scale of Operation
• 18.5. Market Trends
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Key Players - Intensity Mapping
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. India CMO/CDMO Biotechnology Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Services
      • 18.8.1.2.2. By Product
      • 18.8.1.2.3. By Expression Systems
      • 18.8.1.2.4. By Company Size
      • 18.8.1.2.5. By Scale of Operation
  • 18.8.2. Indonesia CMO/CDMO Biotechnology Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Services
      • 18.8.2.2.2. By Product
      • 18.8.2.2.3. By Expression Systems
      • 18.8.2.2.4. By Company Size
      • 18.8.2.2.5. By Scale of Operation
  • 18.8.3. Malaysia CMO/CDMO Biotechnology Market Analysis
    • 18.8.3.1. Introduction
    • 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.3.2.1. By Services
      • 18.8.3.2.2. By Product
      • 18.8.3.2.3. By Expression Systems
      • 18.8.3.2.4. By Company Size
      • 18.8.3.2.5. By Scale of Operation
  • 18.8.4. Thailand CMO/CDMO Biotechnology Market Analysis
    • 18.8.4.1. Introduction
    • 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.4.2.1. By Services
      • 18.8.4.2.2. By Product
      • 18.8.4.2.3. By Expression Systems
      • 18.8.4.2.4. By Company Size
      • 18.8.4.2.5. By Scale of Operation

19. Oceania CMO/CDMO Biotechnology Market 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. Australia
    • 19.3.1.2. New Zealand
  • 19.3.2. By Services
  • 19.3.3. By Product
  • 19.3.4. By Expression Systems
  • 19.3.5. By Company Size
  • 19.3.6. By Scale of Operation
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Services
  • 19.4.3. By Product
  • 19.4.4. By Expression Systems
  • 19.4.5. By Company Size
  • 19.4.6. By Scale of Operation
• 19.5. Market Trends
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Key Players - Intensity Mapping
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. Australia CMO/CDMO Biotechnology Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Services
      • 19.8.1.2.2. By Product
      • 19.8.1.2.3. By Expression Systems
      • 19.8.1.2.4. By Company Size
      • 19.8.1.2.5. By Scale of Operation
  • 19.8.2. New Zealand CMO/CDMO Biotechnology Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Services
      • 19.8.2.2.2. By Product
      • 19.8.2.2.3. By Expression Systems
      • 19.8.2.2.4. By Company Size
      • 19.8.2.2.5. By Scale of Operation

20. Middle East and Africa (MEA) CMO/CDMO Biotechnology Market Analysis 2019-2023 and Forecast 2024-2033

• 20.1. Introduction
• 20.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 20.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 20.3.1. By Country
    • 20.3.1.1. GCC Countries
    • 20.3.1.2. Turkey
    • 20.3.1.3. North Africa
    • 20.3.1.4. South Africa
    • 20.3.1.5. Rest of Middle East and Africa
  • 20.3.2. By Services
  • 20.3.3. By Product
  • 20.3.4. By Expression Systems
  • 20.3.5. By Company Size
  • 20.3.6. By Scale of Operation
• 20.4. Market Attractiveness Analysis
  • 20.4.1. By Country
  • 20.4.2. By Services
  • 20.4.3. By Product
  • 20.4.4. By Expression Systems
  • 20.4.5. By Company Size
  • 20.4.6. By Scale of Operation
• 20.5. Market Trends
• 20.6. Drivers and Restraints - Impact Analysis
• 20.7. Key Players - Intensity Mapping
• 20.8. Country Level Analysis & Forecast
  • 20.8.1. GCC Countries CMO/CDMO Biotechnology Market Analysis
    • 20.8.1.1. Introduction
    • 20.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.1.2.1. By Services
      • 20.8.1.2.2. By Product
      • 20.8.1.2.3. By Expression Systems
      • 20.8.1.2.4. By Company Size
      • 20.8.1.2.5. By Scale of Operation
  • 20.8.2. Turkey CMO/CDMO Biotechnology Market Analysis
    • 20.8.2.1. Introduction
    • 20.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.2.2.1. By Services
      • 20.8.2.2.2. By Product
      • 20.8.2.2.3. By Expression Systems
      • 20.8.2.2.4. By Company Size
      • 20.8.2.2.5. By Scale of Operation
  • 20.8.3. South Africa CMO/CDMO Biotechnology Market Analysis
    • 20.8.3.1. Introduction
    • 20.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.3.2.1. By Services
      • 20.8.3.2.2. By Product
      • 20.8.3.2.3. By Expression Systems
      • 20.8.3.2.4. By Company Size
      • 20.8.3.2.5. By Scale of Operation
  • 20.8.4. North Africa CMO/CDMO Biotechnology Market Analysis
    • 20.8.4.1. Introduction
    • 20.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 20.8.4.2.1. By Services
      • 20.8.4.2.2. By Product
      • 20.8.4.2.3. By Expression Systems
      • 20.8.4.2.4. By Company Size
      • 20.8.4.2.5. By Scale of Operation

21. Market Structure Analysis

• 21.1. Market Analysis by Tier of Companies
• 21.2. Market Share Analysis of Top Players
• 21.3. Market Presence Analysis

22. Competition Analysis

• 22.1. Competition Dashboard
• 22.2. Competition Deep Dive
  • 22.2.1. Patheon N.V.
    • 22.2.1.1. Overview
    • 22.2.1.2. Service/Product Portfolio
    • 22.2.1.3. Sales Footprint
    • 22.2.1.4. Key Financials
    • 22.2.1.5. SWOT Analysis
    • 22.2.1.6. Strategy Overview
      • 22.2.1.6.1. Marketing Strategy
      • 22.2.1.6.2. Service Strategy
      • 22.2.1.6.3. Channel Strategy
  • 22.2.2. Catalent
    • 22.2.2.1. Overview
    • 22.2.2.2. Service/Product Portfolio
    • 22.2.2.3. Sales Footprint
    • 22.2.2.4. Key Financials
    • 22.2.2.5. SWOT Analysis
    • 22.2.2.6. Strategy Overview
      • 22.2.2.6.1. Marketing Strategy
      • 22.2.2.6.2. Service Strategy
      • 22.2.2.6.3. Channel Strategy
  • 22.2.3. Samsung Biologics Co., Ltd
    • 22.2.3.1. Overview
    • 22.2.3.2. Service/Product Portfolio
    • 22.2.3.3. Sales Footprint
    • 22.2.3.4. Key Financials
    • 22.2.3.5. SWOT Analysis
    • 22.2.3.6. Strategy Overview
      • 22.2.3.6.1. Marketing Strategy
      • 22.2.3.6.2. Service Strategy
      • 22.2.3.6.3. Channel Strategy
  • 22.2.4. Lonza.
    • 22.2.4.1. Overview
    • 22.2.4.2. Service/Product Portfolio
    • 22.2.4.3. Sales Footprint
    • 22.2.4.4. Key Financials
    • 22.2.4.5. SWOT Analysis
    • 22.2.4.6. Strategy Overview
      • 22.2.4.6.1. Marketing Strategy
      • 22.2.4.6.2. Service Strategy
      • 22.2.4.6.3. Channel Strategy
  • 22.2.5. Boehringer Ingelheim
    • 22.2.5.1. Overview
    • 22.2.5.2. Service/Product Portfolio
    • 22.2.5.3. Sales Footprint
    • 22.2.5.4. Key Financials
    • 22.2.5.5. SWOT Analysis
    • 22.2.5.6. Strategy Overview
      • 22.2.5.6.1. Marketing Strategy
      • 22.2.5.6.2. Service Strategy
      • 22.2.5.6.3. Channel Strategy
  • 22.2.6. Samsung BioLogics
    • 22.2.6.1. Overview
    • 22.2.6.2. Service/Product Portfolio
    • 22.2.6.3. Sales Footprint
    • 22.2.6.4. Key Financials
    • 22.2.6.5. SWOT Analysis
    • 22.2.6.6. Strategy Overview
      • 22.2.6.6.1. Marketing Strategy
      • 22.2.6.6.2. Service Strategy
      • 22.2.6.6.3. Channel Strategy
  • 22.2.7. AGC Biologics, Inc.
    • 22.2.7.1. Overview
    • 22.2.7.2. Service/Product Portfolio
    • 22.2.7.3. Sales Footprint
    • 22.2.7.4. Key Financials
    • 22.2.7.5. SWOT Analysis
    • 22.2.7.6. Strategy Overview
      • 22.2.7.6.1. Marketing Strategy
      • 22.2.7.6.2. Service Strategy
      • 22.2.7.6.3. Channel Strategy
  • 22.2.8. WuXi Biologics
    • 22.2.8.1. Overview
    • 22.2.8.2. Service/Product Portfolio
    • 22.2.8.3. Sales Footprint
    • 22.2.8.4. Key Financials
    • 22.2.8.5. SWOT Analysis
    • 22.2.8.6. Strategy Overview
      • 22.2.8.6.1. Marketing Strategy
      • 22.2.8.6.2. Service Strategy
      • 22.2.8.6.3. Channel Strategy
  • 22.2.9. AbbVie Inc
    • 22.2.9.1. Overview
    • 22.2.9.2. Service/Product Portfolio
    • 22.2.9.3. Sales Footprint
    • 22.2.9.4. Key Financials
    • 22.2.9.5. SWOT Analysis
    • 22.2.9.6. Strategy Overview
      • 22.2.9.6.1. Marketing Strategy
      • 22.2.9.6.2. Service Strategy
      • 22.2.9.6.3. Channel Strategy
  • 22.2.10. Avid Bioservices, Inc.
    • 22.2.10.1. Overview
    • 22.2.10.2. Service/Product Portfolio
    • 22.2.10.3. Sales Footprint
    • 22.2.10.4. Key Financials
    • 22.2.10.5. SWOT Analysis
    • 22.2.10.6. Strategy Overview
      • 22.2.10.6.1. Marketing Strategy
      • 22.2.10.6.2. Service Strategy
      • 22.2.10.6.3. Channel Strategy
  • 22.2.11. Fujifilm Diosynth Biotechnologies
    • 22.2.11.1. Overview
    • 22.2.11.2. Service/Product Portfolio
    • 22.2.11.3. Sales Footprint
    • 22.2.11.4. Key Financials
    • 22.2.11.5. SWOT Analysis
    • 22.2.11.6. Strategy Overview
      • 22.2.11.6.1. Marketing Strategy
      • 22.2.11.6.2. Service Strategy
      • 22.2.11.6.3. Channel Strategy
  • 22.2.12. Xpress Biologic
    • 22.2.12.1. Overview
    • 22.2.12.2. Service/Product Portfolio
    • 22.2.12.3. Sales Footprint
    • 22.2.12.4. Key Financials
    • 22.2.12.5. SWOT Analysis
    • 22.2.12.6. Strategy Overview
      • 22.2.12.6.1. Marketing Strategy
      • 22.2.12.6.2. Service Strategy
      • 22.2.12.6.3. Channel Strategy
  • 22.2.13. Rentschler Biopharma SE
    • 22.2.13.1. Overview
    • 22.2.13.2. Service/Product Portfolio
    • 22.2.13.3. Sales Footprint
    • 22.2.13.4. Key Financials
    • 22.2.13.5. SWOT Analysis
    • 22.2.13.6. Strategy Overview
      • 22.2.13.6.1. Marketing Strategy
      • 22.2.13.6.2. Service Strategy
      • 22.2.13.6.3. Channel Strategy
  • 22.2.14. KBI Biopharma (JSR Corporation)
    • 22.2.14.1. Overview
    • 22.2.14.2. Service/Product Portfolio
    • 22.2.14.3. Sales Footprint
    • 22.2.14.4. Key Financials
    • 22.2.14.5. SWOT Analysis
    • 22.2.14.6. Strategy Overview
      • 22.2.14.6.1. Marketing Strategy
      • 22.2.14.6.2. Service Strategy
      • 22.2.14.6.3. Channel Strategy
  • 22.2.15. Cytovance Biologics
    • 22.2.15.1. Overview
    • 22.2.15.2. Service/Product Portfolio
    • 22.2.15.3. Sales Footprint
    • 22.2.15.4. Key Financials
    • 22.2.15.5. SWOT Analysis
    • 22.2.15.6. Strategy Overview
      • 22.2.15.6.1. Marketing Strategy
      • 22.2.15.6.2. Service Strategy
      • 22.2.15.6.3. Channel Strategy

23. Assumptions and Acronyms Used

24. Research Methodology